

中国医药外包:现状与前景

China Pharma Outsourcing Market By 2015

By Jim J. Zhang, Ph.D.

January, 2009



Table of Contents

Scope of the Report -----	2
About Author -----	3
Executive Summary -----	13
China’s advantages in pharma outsourcing	
Current market size, service capability and existing issues	
From popular outsourcing models to future development trend: A series of case studies	
Impact of financial crisis: Market development forecasts for 2009 and 2010	
Future development: Years beyond 2010	
Chapter 1: China’s Advantages in Pharma Outsourcing -----	19
Summary -----	20
1.1 Rich natural resources -----	21
1.1.1 Abundant, readily available natural resources -----	21
1. Rich natural products -----	21
2. A large, drug-naïve patient pool -----	21
3. Abundant animal species -----	22
1.2.2 Large, well-trained workforce -----	22
1.2 Advantage of low cost labor -----	24
1.3 Attraction of potentially world largest pharmaceutical market -----	25
1.4 A complete industrial structure with all service elements starts emerging -----	30
1.4.1 Rapid emerging of professional CROs and CMOs founded by Returnees -----	29
1.4.2 Increasing numbers of traditional Chinese pharma and R&D- oriented biotech companies join in outsourcing service -----	30
1.4.3 Influx of a large number of multinational service providers (MNCROs/MNCMOs) -----	31
1.5 Well developed business infrastructure -----	32
1.5.1 Well funded and equipped industrial/technology parks -----	32
1.5.2 R&D centers spreading all over the country -----	33
1.5.3 Well developed transportation system -----	33
1.5.4 Abundant supporting services -----	34
1. Convenient logistics services -----	34
2. Financial service -----	34
3. Lounging -----	35
Chapter 2. Current Market Size, Service Capability and Existing Issues -----	36
Summary -----	37

2.1 Introduction	38
2.2 Current market size	40
2.2.1 Entire industry market size	40
2.2.2 Current market size of each service sector	42
1. Value chain of drug discovery, development and manufacturing process	42
2. Market size of target identification and validation	42
3. Market size of lead discovery and optimization	44
4. Market size of preclinical research	45
5. Market size of clinical research	46
6. Current market size of contract manufacturing	47
7. Market distribution of each service sector	48
2.3 Current service capabilities	50
2.3.1 Current service capability in early stage drug discovery	50
1. Target identification and validation	50
2. Focused compound libraries	53
3. Lead discovery and optimization	56
2.3.2 Current service capability in preclinical research	58
1. <i>In vitro/in vivo</i> pharmacological property study	58
2. <i>In vitro/in vivo</i> ADME/Tox study	62
3. <i>In vivo</i> drug efficacy determination	63
2.3.3 Current service capability in late stage development	63
1. Service capability in clinical research	63
2. Logistics services for clinical trials	67
2.3.4 Current service capability in contract manufacturing	68
1. Service capability in process R&D and scale-up synthesis	68
2. Service capability in API production to support drug development and commercialization	72
2.4 Industry boosted by the participation of Chinese pharma and biotech companies	74
2.4.1 Outsourcing service provided by traditional Chinese pharmaceutical companies	75
2.4.2 Outsourcing service provided by fast growing, R&D-oriented Chinese biotech companies	82
2.5 Existing Issues	91
2.5.1 IP protection	92
2.5.2 Limited service capability	93
2.5.3 Limited skills in drug R&D	96
2.5.4 Majority players still small	97
2.5.5 Regulation in clinical trial and drug approval	99
Chapter 3. From Popular Outsourcing Models To Future Development Trend: A Series of Case Studies	101
Summary	102
3.1 Introduction	103

3.2 Outsourcing in China by major pharma companies: All types -----	105
3.3 Small biotech companies in China: Starting to embrace China opportunity ---	121
3.4 Outsourcing by generic drug makers: To secure supply stability by gaining ownership -----	127
3.4.1 Pure contract manufacturing outsourcing -----	128
3.4.2 Taking partial ownership -----	129
3.4.3 Complete acquisition -----	130
3.4.4 Establishing wholly owned manufacturing facilities -----	130
3.5 Multinational CROs in China: To utilize rich, low cost resources -----	131
3.5.1 Clinical research service providers -----	133
3.5.2 Preclinical research service providers -----	134
3.5.3 Diagnostics and cardiac safety testing service providers -----	135

**Chapter 4. Impact of Financial Crisis: Market Development Forecasts for
2009 and 2010 -----137**

Summary -----	138
4.1 Introduction -----	139
4.2 Biotech companies hit hardest by the financial crisis -----	140
4.3 How terror attack at Mumbai of India will affect China pharma outsourcing industry -----	143
4.4 Qualitative analysis of the impact -----	144
4.4.1 How major pharma and biotech companies will change their outsourcing behavior -----	145
4.4.2 How small biotech companies will change their outsourcing behavior -----	146
1. Financially troubled small biotech companies can survive by outsourcing to China -----	147
2. How small biotech companies safely operate outsourcing in China: some practical advices -----	148
4.4.3 How each service sector will be affected -----	149
1. Impact on early stage drug discovery -----	149
2. Impact on preclinical development -----	150
3. Impact on clinical development -----	151
4. Impact on contract manufacturing -----	152
4.5 Quantitative analysis and forecast of market development for 2009 and 2010 -----	153
4.5.1 Forecast of overall market development -----	153
4.5.2 Market development forecast of each service sector -----	154
4.5.3 How to compare with India pharma outsourcing market -----	156

Chapter 5. Future Development: Years beyond 2010 -----159

Summary -----	160
5.1 Introduction -----	161
5.1.1 Global drug makers still need outsourcing services from China -----	162

5.1.2	Improved outsourcing environment and growing outsourcing demands by domestic companies will also drive the industry to further grow -----	163
5.2	Drivers of the industry's future growth -----	163
5.2.1	Advantage of still low cost labor -----	163
1.	Analysis of labor increase in next seven years -----	163
(1)	Salary increase caused by employee turnover will gradually fall flat -----	165
(2)	China is producing more college graduates than all industries of the country can absorb -----	165
(3)	Living expense throughout entire country still varies dramatically -----	165
(4)	More third tier cities in inner land are being rapidly developed -----	166
2.	Comparison of labor cost increase with other countries -----	166
5.2.2	Improved IP protection environment -----	169
5.2.3	Improved service capability and quality -----	173
5.2.4	Government support -----	174
5.2.5	Increasing outsourcing demands by small biotech companies pressured by financial crisis -----	174
5.2.6	More outsourcing demands by the emerging and growing domestic, R&D-oriented Chinese pharma/biotech companies -----	175
5.3	Will China follow the development model of the West or India? -----	176
5.3.1	Development pattern of Western pharma outsourcing industry -----	176
5.3.2	Development pattern of Indian outsourcing industry -----	178
5.3.3	Which development model would China follow? -----	180
5.4	Forecast of market development by 2015 -----	186
5.4.1	Forecast of China pharma outsourcing market by 2015 -----	187
5.4.2	Forecasts of market development of each service sector by 2015 -----	187
1.	Market development of outsourcing in early stage drug discovery -----	187
2.	Market development of preclinical research outsourcing -----	190
3.	Market development of outsourcing in clinical research -----	191
4.	Market development of contract manufacturing -----	193
(1)	More APIs and finished drugs will be exported to the well regulated markets -----	193
(2)	More cGMP facilities compliance to the Western standards -----	195
(3)	Service capability at traditional Chinese pharma companies will be greatly improved -----	195
5.5	Three outsourcing waves successively drive the future growth-----	198
5.5.1	First wave: Outsourcing by major pharma companies -----	198
5.5.2	Second wave (soon to come): Outsourcing by small biotech companies -----	198
5.5.3	Third wave (to come in near future): Outsourcing by domestic drug companies -----	199

1.	More investment in R&D programs by Chinese pharma and biotech companies -----	199
2.	A growing number of venture capitalists investing in R&D- oriented Chinese pharma and biotech companies -----	199
3.	Chinese government has pledged to increase R&D investment in its pharma industry -----	200
5.6	Forecast of Industry growth pattern -----	201
5.6.1	More competition -----	201
5.6.2	More consolidation -----	202
5.6.3	More large players resulting from alliance with MNCROs -----	204
5.6.4	More Chinese companies will use service from MNCROs -----	205
5.6.5	More Chinese CROs and CMOs will have overseas operations -----	206
5.6.6	More MNCROs/MNCMOs will greatly expand their service facilities in China -----	209
1.	MNCROs/MNCMOs already in China would likely expand their facility and offer more services -----	210
2.	More MNCROs will enter the Chinese market in near future -----	210
5.6.7	More Chinese CROs/CMOs will have internal drug R&D programs -----	213
5.7	Challenges to Chinese CROs and CMOs -----	213
5.7.1	Rising labor cost -----	213
5.7.2	Abiding by the international rule of game -----	214
5.7.3	Competition from CROs/CMOs in other countries -----	215

List of Tables

Table 1.	Comparison of China's technical workforce with other countries -----	23
Table 2.	Comparison of labor cost in various locations of the world (FTE rate) ----	24
Table 3.	China pharmaceutical market: Past development history and future development forecast-----	26
Table 4.	Market growth history of China pharma outsourcing industry -----	40
Table 5.	Current market size of target identification and validation -----	44
Table 6.	Current market size of drug discovery service -----	45
Table 7.	Current market size of preclinical research -----	47
Table 8.	Current market size of clinical research -----	47
Table 9.	Current market size of contract manufacturing service -----	48
Table 10.	Market distribution of each service sector in entire China pharma outsourcing industry (2007 and 2008) -----	49
Table 11.	CROs providing target identification and validation service -----	50
Table 12.	CROs/CMOs providing focused compound libraries -----	54
Table 13.	CROs providing lead discovery and optimization service -----	56
Table 14.	CROs providing preclinical research service -----	59
Table 15.	CROs providing clinical research service -----	65
Table 16.	CROs providing regulatory service -----	67
Table 17.	CROs/CMOs providing contract manufacturing service (including	

chemical process R&D) -----	69
Table 18. CROs/CMOs possessing FDA or EMEA certified cGMP production facility -----	73
Table 19. Chinese pharma companies involved in contract manufacturing service -----	76
Table 20. Major Chinese biotech companies and their capabilities -----	83
Table 21. Classification and definition of contract pharmaceutical research service levels and analysis of where the current service capabilities of China-based CROs/CMOs stand -----	93
Table 22. Comparison of a typical CRO in China, India and a Western country ----	94
Table 23. Market development forecast of China pharma outsourcing industry (2009 and 2010) -----	154
Table 24. Market development forecast of each service sector in 2009 and 2010 -----	155
Table 25. Growth prediction of China's CRO and CMO market in 2009 and 2010 -----	156
Table 26. Comparison of market value between China and India in 2009 and 2010 -----	157
Table 27. Forecast of labor cost climbing in China pharma outsourcing industry (FTE rate) -----	165
Table 28. Comparison of labor cost increase in countries around the world in next seven years (FTE rate) -----	168
Table 29. Comparison of cost saving (%) between China and other countries in 2010 and 2015 -----	169
Table 30. Development history of WuXi PharmaTech and forecast of its future development -----	183
Table 31. Market growth forecast of China pharma outsourcing industry after 2010 -----	186
Table 32. Market growth forecast of early stage drug discovery service after 2010 -----	189
Table 33. Market growth forecast of preclinical research service after 2010 -----	190
Table 34. Market growth forecast of clinical development service after 2010 -----	192
Table 35. Market growth forecast of contract manufacturing service after 2010 -----	197
Table 36. Foreign VCs having invested in Chinese pharma/biotech companies ---	200
Table 37. China-based CROs/CMOs with headquarters/offices in the West -----	206
Table 38. China-based CROs/CMOs founded by Western entrepreneurs -----	211

List of Figures

Figure 1. Development of Chinese pharmaceutical market: Past and future -----	26
Figure 2. Development of each drug market section -----	27
Figure 3. Chinese pharmaceutical market composition of 2008 -----	26
Figure 4. Distributions of Chinese CROs/CMOs in each technical area -----	31
Figure 5. Profile of Suzhou Biobay -----	32
Figure 6. An overview of current situation of China pharma outsourcing industry -	38
Figure 7. Market development of China pharma outsourcing industry -----	41

Figure 8. Value chain of drug discovery, development and manufacturing -----	43
Figure 9. 2008 Market share of each service sector -----	49
Figure 10. An overall picture of outsourcing activities in China -----	104
Figure 11. Summary of latest restructuring activities taken by biotech industry ---	140
Figure 12. Biotech industry under financial crisis -----	142
Figure 13. How outsourcing to China will be affected by financial crisis -----	145
Figure 14. Market value of each service sector in 2009 and 2010 -----	155
Figure 15. China's CRO and CMO market value in 2009 and 2010 -----	156
Figure 16. Comparison of pharma outsourcing market size between China and India -----	157
Figure 17. Climbing of labor cost in China pharma outsourcing industry (between 2008 and 2015) -----	164
Figure 18. Comparison of labor cost increase in China with other countries (from 2008 to 2015) -----	167
Figure 19. Cost saving comparison (%) between China and other countries (in 2010 and 2015) -----	168
Figure 20. WuXi PharmaTech's staff growth history and forecast -----	183
Figure 21. WuXi PharmaTech's revenue growth history and forecast -----	184
Figure 22. Market development forecast of China pharma outsourcing industry after 2010 -----	187
Figure 23. Market development forecast of early stage drug discovery service after 2010 -----	189
Figure 24. Market development forecast of preclinical development service after 2010 -----	191
Figure 25. Market development forecast of clinical development service after 2010 -----	192
Figure 26. Market growth of China's contract manufacturing service after 2010 -----	197

List of Case Studies

Case study 1. Company profile of India's Dr. Reddy's Laboratories -----	98
Case study 2. Company profile of China's Harbin Pharmaceutical Group -----	99
Case study 3. Pfizer in China – Initially falling behind others but becoming more aggressive now -----	106
Case study 4. Sanofi Aventis (SA) in China – Focusing on research -----	108
Case study 5. GlaxoSmithKline (GSK) in China – Determined to turn “Made in China” to “Discovered in China” -----	110
Case study 6. Johnson & Johnson (J&J) in China – Focusing on outsourcing ----	111
Case study 7. Roche in China – Considering China as an important market for its future development -----	112
Case study 8. Novartis in China – Having a long term plan to tap Chinese drug market -----	113
Case study 9. AstraZeneca (AZ) in China: Most active among all major pharma companies in China -----	115
Case study 10. Eli Lilly in China – Taking different approaches than all other peer competitors -----	117

Case study 11. Wyeth in China – Focusing on China’s nutri-ceutics market -----	119
Case study 12. Bayer in China – Focusing on manufacturing and marketing drug products in China -----	118
Case study 13. LEAD Therapeutics with ShangPharma – A risk-sharing model with Chinese CRO investing in client company -----	122
Case study 14. Curis with ChemPartner – To stretch the dollar value of cash reserve by allocating part of drug R&D program to China----	123
Case study 15. ChinaBio Therapeutics – To leverage the full potential of China’s cost-effectiveness by operating entire drug R&D program in China -----	124
Case study 16. Ascenta Therapeutics in China – Strategically positioning -----	125
Case study 17. GNI with Shanghai Genomics – From partnership to acquisition -	126
Case study 18. Bicoll in China – From a technology developer to becoming a contract research service provider -----	127
Case study 19. Boehringer Ingelheim in China -----	128
Case study 20. Krka Pharmaceuticals and Menovo Pharmaceuticals – Krka owning 7.5% stake in Menovo -----	129
Case study 21. Oxea with Chengxing Group – Forming a JV -----	128
Case study 22. Hovione acquired 75% stake of Hisyn Pharmaceutical Co. -----	128
Case study 23. Actavis acquired 90% stake of Zhejiang Chiral Medicine Chemicals -----	130
Case study 24. Degussa in China -----	130
Case study 25. Lonza in China -----	131
Case study 26. Covance in China - Recently established a central lab in Shanghai -----	133
Case study 27. PPD in China -----	133
Case study 28. Quintiles Transnational in China -----	134
Case study 29. MDS Pharma Services in China – Recently established a central Lab in Beijing -----	134
Case study 30. Charles River Laboratories in China: Acquired BioExplorer -----	134
Case study 31. MPI Research in China – Forming a JV with Medicilon -----	135
Case study 32. Bridge Pharmaceuticals in China – Established wholly owned animal testing facility in Beijing -----	135
Case study 33. Biomagnetics Diagnostics in China -----	135
Case study 34. Cordium Links in China – Forming a JV for cardiac safety testing -----	136
Case study 35. AstraZeneca contracting out IP sensitive drug research to Chinese CRO -----	170
Case study 36. Promega Corporation outsourced IP sensitive research to China --	171
Case study 37. Novartis is conducting first-class drug research in China -----	171
Case study 38. Chinese pharma companies following the international rules -----	172
Case study 39. Merger between two Chinese CROs -----	173
Case study 40. Development history of a typical Chinese CRO to demonstrate the development pattern of China pharma outsourcing industry ---	181
Case study 41. A foreign CRO’s development history to illustrate the possible future development pattern of China’s outsourcing industry -----	184

Case study 42. Compound libraries enriched with protein kinase inhibitors -----	188
Case study 43. Fast growing Zhejiang Hisun Pharmaceutical Co. Ltd. -----	193
Case study 44. Fast rising Zhejiang Huahai Pharmaceutical Co. Ltd. -----	194
Case study 45. More China-based CROs/CMOs are preparing for cGMP certification by the FDA and/or the EMEA -----	196
Case study 46. Alliance between two China-based CROs -----	202
Case study 47. Alliance between a Chinese CRO and two foreign CROs -----	203
Case study 48. Alliance of 33 China-based CROs -----	203
Case study 49. Fast growing Shanghai Medicilon by partnering with MPI Research -----	204
Case study 50. Chinese CRO utilizing multinational CRO's technologies -----	205
Case study 51. Global Research Services expanding in China -----	210
Case study 52. Latest entrance by Drug Information Association (DIA) -----	211

Company Index

Professional Chinese CROs and CMOs -----	218
Traditional Chinese pharmaceutical companies involved in outsourcing service -----	219
Chinese biotech companies involved in outsourcing service -----	219
Multinational service providers having service facilities in China -----	220
Chinese research institutions collaborating with Western pharma companies -----	220
Foreign drug companies outsourcing in China -----	222

Appendix

Appendix I. Research methodology -----	224
Appendix II. About JZMed, Inc. -----	225